Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization

Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated... ORIGINAL CONTRIBUTION ONLINE FIRST Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization The TRILOGY ACS Platelet Function Substudy Context The relationship of platelet function testing measurements with outcomes Paul A. Gurbel, MD in patients with acute coronary syndromes (ACS) initially managed medically without David Erlinge, MD revascularization is unknown. E. Magnus Ohman, MB, ChB Objective To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel. Benjamin Neely, MS Design, Setting, and Patients Patients with medically managed unstable angina Megan Neely, PhD or non–ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS Shaun G. Goodman, MD, MSc trial (2008 to 2011) comparing clopidogrel vs prasugrel. Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 Kurt Huber, MD treated with clopidogrel. Mark Y. Chan, MD Interventions Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/ Jan H. Cornel, MD d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose. Eileen Brown, PhD Chunmei Zhou, MS Main Outcome http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Loading next page...
 
/lp/american-medical-association/platelet-function-during-extended-prasugrel-and-clopidogrel-therapy-ECQgsKs0Fb

References (19)

Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.17312
pmid
23117779
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION ONLINE FIRST Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization The TRILOGY ACS Platelet Function Substudy Context The relationship of platelet function testing measurements with outcomes Paul A. Gurbel, MD in patients with acute coronary syndromes (ACS) initially managed medically without David Erlinge, MD revascularization is unknown. E. Magnus Ohman, MB, ChB Objective To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel. Benjamin Neely, MS Design, Setting, and Patients Patients with medically managed unstable angina Megan Neely, PhD or non–ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS Shaun G. Goodman, MD, MSc trial (2008 to 2011) comparing clopidogrel vs prasugrel. Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 Kurt Huber, MD treated with clopidogrel. Mark Y. Chan, MD Interventions Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/ Jan H. Cornel, MD d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose. Eileen Brown, PhD Chunmei Zhou, MS Main Outcome

Journal

JAMAAmerican Medical Association

Published: Nov 7, 2012

There are no references for this article.